CN101837014A - Medicinal composition for treating chronic kidney diseases - Google Patents
Medicinal composition for treating chronic kidney diseases Download PDFInfo
- Publication number
- CN101837014A CN101837014A CN200910129518A CN200910129518A CN101837014A CN 101837014 A CN101837014 A CN 101837014A CN 200910129518 A CN200910129518 A CN 200910129518A CN 200910129518 A CN200910129518 A CN 200910129518A CN 101837014 A CN101837014 A CN 101837014A
- Authority
- CN
- China
- Prior art keywords
- stem cells
- umbilical cord
- kidney
- mesenchymal stem
- cord mesenchymal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a medicinal composition for treating chronic kidney diseases, which comprises mesenchymal stem cells of the umbilical cord.
Description
Technical field
The present invention system is about the technical field of treatment chronic kidney disease.Particularly, the present invention system provides a kind of medical composition of treatment chronic kidney disease, and it comprises umbilical cord mesenchymal stem cells.The present invention still provides a kind of purposes of umbilical cord mesenchymal stem cells, and it is in order to the medicine of preparation for the treatment chronic kidney disease.
Background technology
Because the aging of population is added the change on compatriots' dietary habit, cause diabetes and cardiovascular disease constantly soaring in recent years, the prevalence rate of chronic kidney disease also increases year by year.Present chronic kidney disease has been in the 8th of compatriots' ten big causes of the death, and the trend that becomes the new state in Taiwan disease is gradually arranged.According to statistics, Taiwan has more than 200 ten thousand common people to suffer from chronic kidney disease at present approximately, and entering into the sufferer that latter stage, renal failure was washed kidney then has more than 60,000 approximately, and annual rate of growth with 6% is being grown up.Though the increase of chronic kidney disease sufferer is the trend in the whole world, points out that according to research Taiwan chronic kidney disease prevalence rate up to 11.9%, occupies in the third place in the world.Therefore, how preventing the generation of chronic kidney disease and treatment chronic kidney disease is medically crucial now problem.
Stem cell therapy is the new distant view for the treatment of at present.Human umbilical cord mesenchymal stem cells is the refuse after a kind of the production, and the source is obtained easily, does not have the morals misgivings, and processing mode is simple, and numbers of poles is many, a kind of fast source of human stem cell of breeding.This laboratory before also worked out, and transplanted human umbilical cord mesenchymal stem cells in the rat striatum, and the cell of implantation can be survived in brain tissue of rat four months, represented human umbilical cord mesenchymal stem cells, can not cause host's immunity and rejection.Therefore, human umbilical cord mesenchymal stem cells is the good source of human stem cell that a strain is suitable for carrying out heteroplastic transplantation.Simultaneously, after we utilize carbon tetrachloride to bring out the rat hepatic fibrosis, directly implant human umbilical cord mesenchymal stem cells in the liver of mouse, find not only can effectively reduce GOT and GTP in the rat serum, and can effectively help the reparation of hepatic fibrosis.
Summary of the invention
On the one hand, the invention provides a kind of medical composition that is used for the treatment of chronic kidney disease, it comprises umbilical cord mesenchymal stem cells (umbilical mesenchymal stem cells).Specific, described medical composition can reduce blood urea nitrogen in the serum, reduce kreatinin in the serum, increases Ccr, reduces protein content and the inflammation of reduction kidney in the urine.In an instantiation, the implantable kidney position of described medical composition to individuality.In another instantiation, described umbilical cord mesenchymal stem cells is from the mankind.
On the other hand, The present invention be directed to a kind of purposes of umbilical cord mesenchymal stem cells, it is in order to the medicine of preparation for the treatment nephropathy.Specific, described medicine can reduce blood urea nitrogen in the serum, reduce kreatinin in the serum, increases Ccr, reduces protein content and the inflammation of reduction kidney in the urine.In an instantiation, the implantable kidney position of described medicine to individuality.In another instantiation, described umbilical cord mesenchymal stem cells is from the mankind.
Description of drawings
Described and the embodiment of preamble can reach better description effect by accompanying drawing.In order to strengthen explanation of the present invention, the graphic of suitable embodiment is recited in this.Be noted that the present invention is not limited to be recited in this explanation.
Fig. 1 to 4 shows the various analysis results of kidney interstitial fibers blast cell after TGF β-1 handles.
Fig. 5 and 6 shows after the human umbilical cord mesenchymal stem cells implantation, the change of rat kidney outward appearance kenel.
Fig. 7 to 11 shows the tissue slice figure of rat kidney behind the Hematoxylin-Eosin tissue staining.
Figure 12 to 17 shows the tissue slice figure of rat kidney behind Sirius red tissue staining.
Figure 18 to 20 shows the every analysis after rat is transplanted human umbilical cord mesenchymal stem cells.
Figure 21 shows the blood urine biochemistry detection analysis after rat is transplanted human umbilical cord mesenchymal stem cells.
The specific embodiment
Unless otherwise defined, used herein all technology and science vocabulary have the affiliated skill person of this paper of haveing the knack of institute clear same meaning usually.
In this article, article " " means the grammatical object of this article of one or more (that is, at least one).For example, " assembly " means an assembly or the assembly more than.
On the one hand, the invention provides a kind of medical composition that is used for the treatment of chronic kidney disease, it comprises umbilical cord mesenchymal stem cells (umbilical mesenchymal stem cells).
This paper employed " umbilical cord mesenchymal stem cells " speech means and is positioned at the mammal umbilical cord, is preferably the stem cell in the human umbilical cord mesenchymal tissue, can be not purified cell culture or the cell behind the purification.Following example explanation obtains the flow process of umbilical cord mesenchymal stem cells from the individuality tissue.The umbilical cord garbage in puerperal of making a living, the source is obtained easily, does not have the morals misgivings, and processing mode is simple, and numbers of poles is many, breeding is quick.And this laboratory was before found, transplanted human umbilical cord mesenchymal stem cells, can not cause that the host produces immunological rejection.So human umbilical cord mesenchymal stem cells is a kind of good source of human stem cell that is fit to be used for carrying out heteroplastic transplantation.
This paper employed " medical composition " is meant a kind of mixture as medicine, it contains carrier usually, such as, carrier that medicine can be accepted or excipient, it is known and suitable the dispensing to object in the skill, with as therapeutic, diagnostic or preventative purpose, it also can comprise cell culture or cell.The form of medical composition can be solution, suspension, lozenge, pill, capsule or powder, and its administering mode is preferably injection.
This paper employed " carrier that medicine can be accepted " means filler, diluent, encapsulate capsule material, composite adjuvant or the excipient of non-toxic solid, semisolid or the liquid of any known type.The carrier that medicine can be accepted ties up under the used dosage and concentration, to receiver's avirulence, and can with other composition compatibility of this composite.General equal can the obtaining easily of the carrier that medicine can be accepted by the public.In addition, the auxiliary substance that medicine can be accepted, such as, pH regulator and buffer agent, osmotic pressure regulator, tranquilizer, wetting agent and analog also all can be obtained by the public.
Suitable carrier includes, but not limited to water, glucose, glycerol, saline, ethanol and combination thereof.
Carrier can contain extra reagent, such as, moistening and emulsifying agent, pH buffer agent or adjuvant, it can strengthen the effectiveness of this composite.The locality carrier comprises liquid petroleum, isopropyl palmitate, Polyethylene Glycol, ethanol (95%), Vinlub 73 soluble in water (5%) or sodium lauryl sulphate soluble in water (5%).Can optionally add other material, such as, antioxidant, wetting agent, viscosity stabiliser and similar reagents.
The present invention's medical composition can be used for treating the chronic kidney disease of individuality, and individuality is preferably mammal, is more preferred from the mankind.Specific, described medical composition can reduce blood urea nitrogen in the serum, reduce kreatinin in the serum, increases Ccr, reduces protein content and the inflammation of reduction kidney in the urine.In an instantiation, described medical composition implantable kidney position, the particularly position of kidney connective tissue tunicle lower floor to individuality.In another instantiation, described umbilical cord mesenchymal stem cells is from the mankind.
On the other hand, the invention provides a kind of purposes of umbilical cord mesenchymal stem cells, it is in order to the medicine of preparation for the treatment chronic kidney disease.Specific, described medicine can reduce blood urea nitrogen in the serum, reduce kreatinin in the serum, increases Ccr, reduces protein content and the inflammation of reduction kidney in the urine.In an instantiation, described medicine implantable kidney position, the particularly position of kidney connective tissue tunicle lower floor to individuality.In another instantiation, described umbilical cord mesenchymal stem cells is from the mankind.
The specification specified of each instantiation of the present invention as after.The present invention's further feature will be via the detailed description in following each instantiation and claim and clear presenting.This field tool knows that usually the knowledgeable can understand the present invention and have various aspects, and following instantiation is only in order to explanation but not as the present invention's restriction.
Example
Following example is inquired into human umbilical cord mesenchymal stem cells to warp earlier in the cell culture mode
The influence of the kidney fibroblast strain that TGF β-1 stimulates.The result shows, stimulates the strain of metanephros fibroblast through TGF β-1, can increase at the ratio of S phase and G2/M phase, and causes its hypertrophy, disengages a large amount of collagen protein.Yet, in human umbilical cord mesenchymal stem cells and kidney fibroblast strain co-cultivation system, can observe human umbilical cord mesenchymal stem cells, can effectively reduce and be subjected to the increase ratio of TGF β-1 stimulation metanephros fibroblast strain in S phase and G2/M phase, and reduce its hypertrophy, reduce the collagen protein that it disengages.
Follow-uply carry out 5/6ths excisions, cause the situation of renal fibrosis with the rat kidney,
Implant human umbilical cord mesenchymal stem cells immediately, reaching the situation of observing the kidneys reparation after six weeks all around.The result shows, implants human umbilical cord mesenchymal stem cells, from reaching the phenomenon that cross section organization charts finds that stem cell can effectively be slowed down renal fibrosis in appearance.Via the mensuration on the renal function, also can find to implant human umbilical cord mesenchymal stem cells and can effectively reduce kreatinin in blood urea nitrogen in the serum, the serum, increase Ccr, reduce protein content in the urine.And on tissue slice, also can observe the situation that the collagen protein synthetic quantity increases in the atrophy, kidney of hypertrophy, the renal tubules of interstitial cell in the kidney pompon, and the kidney pompon contains a large amount of monocytes and macrophage and activatory fibroblast, all effectively is improved after implanting human umbilical cord mesenchymal stem cells.
Example 1: the preparation of human umbilical cord mesenchymal cell
Human umbilical cord is collected in sterile working's mode and be stored in HBSS (BiochromL201-10) under 4 ℃ and is no more than 24 hours.
Umbilical cord earlier bubble in 75% ethanol 30 seconds with sterilization.The umbilical cord that to sterilize in sterile working's platform places no calcium and does not have the buffer solution of magnesium ion (CMF, Gibco 14185-052),, and wherein blood vessel and mesenchymal tissue (watt Dun Shi gel) is removed the umbilical cord rip cutting with the utensil of sterilizing.Mesenchymal tissue is cut into 0.5 cubic centimeter fritter, centrifugal 5 minutes with 250 * g.Remove supernatant, and with an amount of serum-free DMEM (Gibco 12100-046) washing and precipitating thing secondary, centrifugal 5 minutes again with 250 * g.Mesenchymal tissue was handled 14 to 18 hours with collagenase under 37 ℃, after the cleaning, handled 30 minutes down in 37 ℃ and concussion with 2.5% trypsin again.Add FBS (HycloneSH30071.03) to mesenchymal tissue to stop the Trypsin reaction.This moment, mesenchymal tissue became mesenchymal cell.After mesenchymal cell makes its dispersion and calculates its quantity with 10%FBS-DMEM, just can be directly used in cultivation and carry out subsequent experimental.
Example 2: the cultivation of kidney interstitial fibers parent cell line
Normal mouse kidney interstitial fibers parent cell line (Normal rat kidney fibroblast cells, NRK-49F; Available from Foodstuff Industrial Development Inst. of Financial Group Legal Persons), the cryovial that will contain the NRK-49F cell thaws with 37 ℃ of water-baths fast, the culture fluid that picks up in the pipe is collected in the 50ml centrifuge tube that contains 10ml 10%CS (PAA B15-001) DMEM, centrifugal 1200rpm, 5 minutes, after removing supernatant, add 10%CS DMEM again, clean 3 times, the 10%CS DMEM that adds 4ml afterwards again, fully mixed back counting cells, (cell density is 5 * 105/dish) in 10 centimeters culture dish with the cell kind, when treating that cell length to eight minute is full, can carry out following experiment.
Example 3: in human umbilical cord mesenchymal stem cells and the kidney fibroblast strain co-cultivation system, can see
Examine human umbilical cord mesenchymal stem cells, can effectively reduce be subjected to TGF β-1 and stimulate after, the kidney fiber
The hypertrophy ratio of blast cell, and effectively reduce disengaging of collagen protein.
We utilize the fluorescence intensity of PI, measure the kidney fibroblast extent of damage.Because the cell that process Triton X-100 handled, can cause the impaired of cell membrane, its DNA all can be indicated by PI, thereby makes G2/M phase be the dna replication dna phase, the fluorescence intensity that its PI showed should be the twice of G1 phase, can judge the variation of cell cycle by this.
Kidney interstitial fibers blast cell after TGF β-1 handles 24 hours, is utilized the impaired situation of flow cytometry analysis cell.The result shows, control group cell average fluorescent strength with handle kidney interstitial fibers blast cell through TGF β-1, its average fluorescent strength is as good as, so TGF β-1 can't cause kidney interstitial fibers blast cell death (Fig. 1).Similarly, utilize the variation of flow cytometry analysis cell cycle.Kidney interstitial fibers blast cell after TGF β-1 handles, ratio in S phase and G2/M phase increases, expression TGF β-1 can promote the hypertrophy of kidney interstitial fibers blast cell, when human umbilical cord mesenchymal stem cells and kidney interstitial fibers blast cell co-cultivation, after giving TGF β-1 stimulation, human umbilical cord mesenchymal stem cells can effectively reduce the ratio (Fig. 2) of kidney interstitial fibers parent cell line in S phase and G2/M phase, and (there were significant differences with the control group for the * table for n=3, p＜0.05; There were significant differences with the kidney interstitial fibers blast cell experimental group that adds TGF β-1 for the # table).
In addition, we as being subjected to matter, measure the activity of dehydrogenase in the survivaling cell Mitochondria with MTT, with the detecting cell survival rate, and then the hypertrophy situation of analysis of cells.Found that, after TGF β-1 handles 24 hours, can cause the hypertrophy of kidney interstitial fibers blast cell, human umbilical cord mesenchymal stem cells and kidney interstitial fibers blast cell co-cultivation and give TGF β-1 stimulation after, human umbilical cord mesenchymal stem cells can effectively reduce the outgrowth situation of kidney interstitial fibers blast cell, and there is not significant difference (Fig. 3) (there were significant differences with the control group for the * table for n=9, p＜0.05) with the control group.
Moreover we are with the concentration of SircolTM Soluble Collagen Assay kit detecting kidney interstitial fibers collagen protein that blast cell is disengaged.The result shows, handle TGF after β-124 hour, the proteic content of collagen significantly rises in its kidney interstitial fibers blast cell culture fluid, when human umbilical cord mesenchymal stem cells and kidney interstitial fibers blast cell co-cultivation and after giving TGF β-1 stimulation, human umbilical cord mesenchymal stem cells can reduce the collagen concentration that kidney interstitial fibers blast cell disengages, and there is not significant difference (Fig. 4) (there were significant differences with the control group for the * table for n=3, p＜0.05) with the control group.
Example 4: implant human umbilical cord mesenchymal stem cells, can effectively reduce rat because of ligation renal artery institute
Cause the phenomenon of renal fibrosis
Male white rat according to people's such as Floege kidney 5/6ths excisions, is all extractd the right side kidney of rat, 2/3rds blood vessels of left kidney ligation, cause rat renal fibrosis (renal mass reduction, RMR).After human umbilical cord mesenchymal stem cells implantation, observe the change of its kidney outward appearance kenel, the result shows that kidney has the Fibrotic situation of obvious reparation (Fig. 5).Similarly, the situation of tissue inflammation mainly is not diffused into inside (Fig. 6) in the periphery of kidney after can observing the implantation stem cell on the organizational patterns of kidney cross section.
Example 5: transplant human umbilical cord mesenchymal stem cells, can effectively slow down rat because of ligation renal artery institute
Cause the Fibrotic phenomenon of glomerule
Will organize slide place Hematoxyline to do nucleus dyeing 30 minutes with filter paper filtering, will organize slide to put back to after dyeing finishes to clean in the secondary water 2 times each 30 seconds.Then will organize slide to insert and do Cytoplasm dyeing in 2 minutes, will organize slide to be put into Aceric acid afterwards and move back and dye 5 seconds with colour generation among the Eosin Y solution 0.2% of filter paper filtering.
The tissue slice figure (Fig. 7) of normal rat left kidney behind the Hematoxylin-Eosin tissue staining.Tissue staining figure (Fig. 8) after around the control group.After control organized for six weeks, tissue staining figure (Fig. 9).After around the rat renal transplantation stem cell, through Hematoxylin-Eosin tissue staining photo (Figure 10).After six weeks of rat renal transplantation stem cell, tissue staining figure (Figure 11).Around the kidney of rat causes behind the renal fibrosis with six weeks, we calculate control group and stem cell group kidney pompon inner cell number respectively, the result shows, control group rat is compared with normal group at incrustation district near-end kidney pompon inner cell number, around no matter being or six weeks remarkable increase was arranged all, and stem cell group around and during six weeks cell number compared with the control group and shown descend (S table incrustation district, P table incrustation proximal end region, D table incrustation remote locations Scale bar:1mm inA, 100 μ m in B, C, D).
Example 6: transplant human umbilical cord mesenchymal stem cells, can effectively reduce rat because of ligation renal artery institute
The synthetic quantity that causes interior Fibrotic area of kidney and collagen protein
Insert with colour generation in the 0.1%Sirius Red stain of filter paper filtering 8 minutes organizing slide.Get the nephridial tissue section of a rat left side behind Sirius red tissue staining, demarcate the content of collagen protein, and the red area that will contain a large amount of collagen protein is defined as the incrustation district with Sirius red stain.In the nephridial tissue of normal rat, do not observe the zone (Figure 12 A) of incrustation.Rat around the control group can be seen incrustation district (Figure 12 B) in the nephridial tissue outside, in addition, organizes the rat in six weeks in control, and its incrustation zone is significantly increased, and toward interior expansion (Figure 12 C).Around transplanting stem cell group, its obviously minimizing (Figure 12 D) of incrustation zone.Organized for six weeks the transplanting stem cell, the regional edge (Figure 12 E) that diminishes and be distributed in tissue of its incrustation.(scale is 1mm) statistical result showed, normal group almost do not have the existence in incrustation zone, and around the control group and six weeks, and its incrustation district area percentage increases and apparently higher than normal group.And six weeks compared the situation that remarkable minimizing is all arranged all around via reaching around the human umbilical cord mesenchymal stem cells group of transplanting to reach in six weeks with the control group.The tissue slice figure (Figure 13) of normal rat left kidney behind Sirius red tissue staining.The tissue staining figure (Figure 14) of kidney after 5/6ths excisions cause around the renal fibrosis.The rat kidney causes renal fibrosis after six weeks through 5/6ths excisions, tissue staining figure (Figure 15).After around the human umbilical cord mesenchymal stem cells of rat renal transplantation, through Sirius red tissue staining photo (Figure 16).The human umbilical cord mesenchymal stem cells of rat renal transplantation is after six weeks, tissue staining figure (Figure 17).(S table incrustation district, P table incrustation proximal end region, D table incrustation remote locations, the A scale is 1mm, B, C, D scale are 100 μ m)
Example 7: transplant human umbilical cord mesenchymal stem cells, can reduce rat and cause because of the ligation renal artery
The content of the fibroblast of monocyte, macrophage and activated state in the kidney, and can find
The human umbilical cord mesenchymal stem cells of implanting extensively is present in the glomerule
ED-1 finds expression in monocyte and the macrophage of rat, when its a large amount of performance expression inflammatory responses just carry out.(α-SMA) be present in endovascular smooth muscle cell also exists in the meat fiber blast cell simultaneously α-smooth muscle actin, so have fibroblast to be activated when it shows expression.Utilize antibody A nti-Human Nuclei to demarcate the position that is present in people's nucleoid place in the rat kidney.
Found that in back (Figure 18 B) and six weeks (Figure 18 C) around the control group, monocyte and macrophage content are compared the trend that increase is arranged with normal group (Figure 18 A) in the kidney; And implant the group of human umbilical cord mesenchymal stem cells, no matter be around (Figure 18 D) or six weeks (Figure 18 E), monocyte and macrophage content in its kidney have the situation of relative minimizing.α-SMA performance expression fibroblast is activated.Found that in back (Figure 19 B) and six weeks (Figure 19 C) around the control group, the fibroblast of activated state is compared the trend that increase is arranged with normal group (Figure 19 A) in the kidney; And implant stem cell, no matter be around (Figure 19 D) or six weeks (Figure 19 E), the fibroblast of activated state in its kidney has the situation of relative minimizing.The human umbilical cord mesenchymal stem cells of rat renal transplantation is after six weeks, do histogenic immunity dyeing with Anti-human specific nuclei antigen antibody, the human umbilical cord mesenchymal stem cells that found that implantation extensively is present in the kidney pompon (Figure 20 A), and can find from the figure that amplifies that human umbilical cord mesenchymal stem cells is present on the blood capillary webmaster of kidney pompon (arrow of Figure 20 D).But on the tissue slice of control group mouse, all do not dyed, be not found to any cell (Figure 20 B, 20E) in the kidney pompon by Anti-human nuclei antigen antibody.Simultaneously, we, do the dyeing of tissue, but do not add Anti-human nuclei antigen antibody after six weeks at the human umbilical cord mesenchymal stem cells of rat renal transplantation, also with the same exist (Figure 20 C, the F) that can't find any cell of control group.(scale is 100 μ m)
Example 8: transplant human umbilical cord mesenchymal stem cells, can effectively reduce rat because of ligation renal artery institute
Cause the loss of renal function
Male white rat with intraperitoneal anesthesia after, with human umbilical cord mesenchymal stem cells 5 * 10
5Individual cell is with the position of Hamilton pin implantation rat left side kidney connective tissue tunicle lower floor (subcapsule).
The experiment rat is before operation, around after kidney 5/6ths excisions and around behind six weeks and the human umbilical cord mesenchymal stem cells of implantation and after six weeks, extract the tail about 1ml of venous blood and utilize metabolic cage to collect 24 hours urine of mouse, wait to deliver northern flourish check portion and detect blood urea nitrogen (blood urea nitrogen in the serum with Binesion, BUN), (the plasma creatinine of kreatinin in the serum, Pcr), (the urine creatinine of kreatinin in the urine, the Cl of concentration Ucr) and calculating kreatinin (creatinine clearance, Ccr).Urine is also surveyed with the quantification of protein method of Bradford simultaneously and is ordered Protein content in the urine.
The result shows, the rat (RMR+HUMSCs) of causing fibrosis and implanting human umbilical cord mesenchymal stem cells, and the content of BUN is compared with the control group of not transplanting stem cell in its serum, and the situation (Figure 21 A) of obvious reduction is arranged.Similarly, the rat (RMR+HUMSCs) of implanting human umbilical cord mesenchymal stem cells, the content of Pcr is compared with the control group rat of not transplanting stem cell in its serum, and the situation (Figure 21 B) of obvious reduction is arranged.Implant the rat of human umbilical cord mesenchymal stem cells, the content of Ccr is compared with control group rat in its serum, the situation that is significantly increased (Figure 21 C).5/6ths excisions of carrying out kidney cause the control group rat (RMR) of renal fibrosis, and the content of its urine protein is compared the situation that is significantly increased with the normal group rat.And the rat of implanting human umbilical cord mesenchymal stem cells, Protein content is compared with control group rat in its urine, and the situation of obvious reduction is arranged, and does not have difference (Figure 21 D) with the normal group rat.
To sum up, we confirm that human umbilical cord mesenchymal stem cells has the effect and the using value of treatment chronic kidney disease.
Claims (10)
1. medical composition that is used for the treatment of chronic kidney disease, it comprises umbilical cord mesenchymal stem cells (umbilical mesenchymal stem cells).
2. according to the medical composition of claim 1, it is characterized by and to reduce kreatinin in blood urea nitrogen in the serum, the reduction serum, increase Ccr, reduce protein content and the inflammation of reduction kidney in the urine.
3. according to the medical composition of claim 1 or 2, it is characterized by implantable kidney position to individuality.
4. according to the medical composition of claim 1 or 2, it is characterized by umbilical cord mesenchymal stem cells system from the mankind.
5. according to the medical composition of claim 4, it is characterized by umbilical cord mesenchymal stem cells system from the mankind.
6. a umbilical cord mesenchymal stem cells is used for the purposes of preparation for the medicine of treatment chronic kidney disease.
7. according to the purposes of claim 6, it is characterized by this medicine and can reduce blood urea nitrogen in the serum, reduce kreatinin in the serum, increase Ccr, reduce protein content and the inflammation of reduction kidney in the urine.
8. according to the purposes of claim 6 or 7, it is characterized by the implantable kidney position of this medicine to individuality.
9. according to the purposes of claim 6 or 7, it is characterized by umbilical cord mesenchymal stem cells system from the mankind.
10. purposes according to Claim 8 is characterized by umbilical cord mesenchymal stem cells system from the mankind.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910129518A CN101837014A (en) | 2009-03-20 | 2009-03-20 | Medicinal composition for treating chronic kidney diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910129518A CN101837014A (en) | 2009-03-20 | 2009-03-20 | Medicinal composition for treating chronic kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101837014A true CN101837014A (en) | 2010-09-22 |
Family
ID=42740850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910129518A Pending CN101837014A (en) | 2009-03-20 | 2009-03-20 | Medicinal composition for treating chronic kidney diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101837014A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017132744A (en) * | 2016-01-29 | 2017-08-03 | 学校法人東京女子医科大学 | Cell sheet composition for inhibiting progress of kidney disease, method for producing the same, and method for inhibiting progress of kidney disease by using the same |
| CN108374013A (en) * | 2018-03-31 | 2018-08-07 | 徐州医科大学附属医院 | It is a kind of enhancing amniotic fluid stem cell anti-oxidation stress ability gene and its application |
-
2009
- 2009-03-20 CN CN200910129518A patent/CN101837014A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017132744A (en) * | 2016-01-29 | 2017-08-03 | 学校法人東京女子医科大学 | Cell sheet composition for inhibiting progress of kidney disease, method for producing the same, and method for inhibiting progress of kidney disease by using the same |
| US10688133B2 (en) | 2016-01-29 | 2020-06-23 | Tokyo Women's Medical University | Cell sheet composition for inhibiting progression of renal disorder, method of producing the same, and method of inhibiting progression of renal disorder using the same |
| CN108374013A (en) * | 2018-03-31 | 2018-08-07 | 徐州医科大学附属医院 | It is a kind of enhancing amniotic fluid stem cell anti-oxidation stress ability gene and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7469422B2 (en) | Liposuction device and system and method of use | |
| DE60123293T2 (en) | HUMAN, UNIBILITATED SOMATIC STEM CELLS DERIVING FROM CORDIAL BLOOD (USSC) | |
| CN105112357A (en) | Adherent cells from placenta and use of same in disease treatment | |
| CN103361300A (en) | Conditioned medium for making highly-purified amnion-derived cell compositions | |
| WO1998032840A1 (en) | Method for separating cells | |
| BE1024781B1 (en) | STRUCTURAL STEM CELLS FROM ADIPOSIVE FABRICS FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT COMPLEX PERIANAL FISTLES AT MORBUS CROHN | |
| MX2011001730A (en) | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions. | |
| CN102198156A (en) | Pharmaceutical composition for treatment of skin wound | |
| Quimby et al. | Novel treatment strategies for feline chronic kidney disease: A critical look at the potential of mesenchymal stem cell therapy | |
| US8673639B2 (en) | Methods for isolating stem cells | |
| Haque et al. | IgE antibody-mediated cytotoxicity of rat macrophages against microfilaria of Dipetalonema citeae in vitro. | |
| CN109646458A (en) | Use the method for placenta mesenchyma stem cell preparation for treating hardening illness | |
| CN107488627A (en) | A kind of biological gel for treating intractable skin injury and its application | |
| CN101837014A (en) | Medicinal composition for treating chronic kidney diseases | |
| Stenvinkel et al. | Implantation of autologous selected renal cells in diabetic chronic kidney disease stages 3 and 4—clinical experience of a “first in human” study | |
| ATE442434T1 (en) | METHOD FOR SUPPRESSING AN IMMUNE SYSTEM REACTION AGAINST TISSUE OR CELL TRANSPLANTS | |
| CN107670109A (en) | The allogeneic valve transformed through bioengineering | |
| Aw Yong et al. | A Bioreactor for 3D In Vitro Modeling of the Mechanical Stimulation of Osteocytes | |
| CN106110302A (en) | The stem cell medicine for the treatment of diabetic foot | |
| CN103756957B (en) | A kind of method of wash-out endothelial progenitor cells from placenta | |
| CN105213523A (en) | A kind ofly from Rhizoma Coptidis, extract the method for active ingredient and the purposes of this extract | |
| CN100406058C (en) | Placenta factor, preparation method and application | |
| EP3070164A1 (en) | System and method for providing isolated concentrated multipotent stromal cells for administration | |
| EP1571204A1 (en) | Leukocyte stimulation matrix | |
| CN102861105A (en) | Method for curing cardiovascular diseases by using cells from adipose tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100922 |